Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Latest Market Insights for the Calcium Channel Blocker Industry?

The market size for calcium channel blockers has seen a substantial increase in the past few years. The figures are set to rise from $15.56 billion in 2024 to $16.46 billion in 2025, marking a compound annual growth rate (CAGR) of 5.8%. The previous growth can be linked to factors such as an increase in cardiovascular disease cases, an elderly population, progress in medical research, lifestyle transformations, and enhanced awareness.

The market for calcium channel blockers is projected to experience robust expansion in the upcoming years. It is anticipated to reach $21.59 billion by 2029, with a compound annual growth rate (CAGR) of 7.0%. The projected growth during this period can be ascribed to the increasing worldwide prevalence of cardiovascular diseases, trends in personalized medicine, improved access to healthcare services, expanded indications, regulatory endorsements, and market developments. The forecast period also foresees trends such as market expansion, technological progression, regulatory scenarios, competitive analysis, patient choices, and increased awareness.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9428&type=smp

What Forces Are Driving The Growth Of The Calcium Channel Blocker Industry?

The rise in cardiovascular diseases is predicted to propel the calcium channel blocker market’s expansion. Cardiovascular disease, which affects the heart and blood vessels, is increasing in prevalence, leading to a greater demand for calcium channel blockers (CCBs), which help reduce the risk of stroke and heart failure. For example, a report by the American College of Cardiology from August 2022, a US-based non-profit medical group, predicts that all four cardiovascular risk factors will surge from 2025 to 2060 in the United States. The most significant increase is anticipated in diabetes cases, rising by 39.3% to reach 55 million, followed by dyslipidemia (27.6% to 126 million), hypertension (25.1% to 162 million), and obesity (18.3% to 126 million). The researchers also noted that strokes (33.8% increase to 15 million) and heart failure (33.4% to 13 million) are anticipated to see the most significant rises in cardiovascular disease rates, followed by ischemic heart disease (30.7% to 29 million) and heart attacks (16.9% to 16 million). As a result, the escalating rates of cardiovascular diseases are contributing to the growth of the calcium channel blocker market.

What Is The Overview Of Market Segmentation In The Calcium Channel Blocker Industry?

The calcium channel blocker market covered in this report is segmented –

1) By Drug Class: Dihydropyridine, Benzothiazepine, Phenylalkylamine, Other Drug Classes

2) By Disease Indications: Hypertension, Chest Pain, Arrhythmias

3) By Route Of Administration: Oral, Parenteral, Other Route Of Administration

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Dihydropyridine: Amlodipine, Nifedipine, Felodipine, Nicardipine, Isradipine

2) By Benzodiazepine: Diazepam

3) By Phenylalkylamine: Verapamil

4) By Other Drug Classes: Bepridil, Lercanidipine, Cilnidipine

What Future Market Trends Are Projected For The Calcium Channel Blocker Industry?

The primary trend gaining traction in the calcium channel blocker market is product innovation. Major players in this market are concentrating on the creation of novel products to maintain their market standing. For example, CMP Pharma, a pharmaceutical manufacturer based in the United States, unveiled Norliqva in June 2022. This product is the first and only oral liquid form of the besylate salt of amlodipine, a long-acting calcium channel blocker. The distinctive characteristic of Norliqva is its format – an amlodipine liquid solution, designed to treat hypertension in individuals aged six and above. Unlike conventional treatment methods, Norliqva eradicates the challenges and inconsistencies connected with crushing or fabricating amlodipine tablets, guaranteeing steadiness in dosage and bioequivalence. This product targets a demography of patients who are prescribed amlodipine but struggle with swallowing or are unable to swallow.

Who Are The Primary Players Operating Across The Global Calcium Channel Blocker Market?

Major companies operating in the calcium channel blocker market include Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Bausch Health Companies Inc., Lupin Pharmaceuticals Inc., Cadila Healthcare Limited, Covis Pharma BV, Glenmark Pharmaceuticals Inc., Amneal Pharmaceuticals LLC, Sofgen Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Knoll Healthcare Private Limited, Sanofi S.A., Clearsynth Labs Ltd., Searle LLC, Bayer AG, AstraZeneca plc, Wyeth-Ayerst Lederle Inc., GlaxoSmithKline Plc., AbbVie Inc., Silvergate Pharmaceuticals Inc., Exela Pharma Sciences LLC, Arbor Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/calcium-channel-blocker-global-market-report

Which Region Offers The Most Growth Potential For The Calcium Channel Blocker Market Through 2029?

North America was the largest region in the calcium channel blocker market in 2024. The regions covered in the calcium channel blocker market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=9428&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model